ACHN stock has gained 70% today after it was announced that Alexion Pharmaceuticals (NASDAQ:ALXN) would acquire Achillion Pharmaceuticals (NASDAQ:ACHN) in a deal worth $930 million USD.
Alexion to Pay 73% Premium on ACHN StockIn a move that will allow Alexion to consolidate its status as a market leader in treating rare blood disorders, it will pay a 73% premium in order to take control of Achillion’s two experimental treatments for paroxysmal nocturnal hemoglobinuria (PNH), a market it has dominated with its flagship drug Soliris. Alexion Pharmaceuticals now faces various patent challenges and is attempting to ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.